Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis

NCT00446992 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT00446992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2006
Completion date
March 31, 2010
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia